GB

Geoffrey Brooke

Cynata Therapeutics Limited | Non-Executive Director, Non-Executive Chairman
Mr Brooke joined the Board in June 2016. He founded GBS Venture Partners Pty Ltd in 1996 and has more than 20 years of venture capital experience. In January 2014, he reduced his involvement in GBS and is now special adviser to the firm and its funds. Mr Brooke was formally President of Medvest Inc., a US-based early-stage venture capital group he founded with Johnson & Johnson. Mr Brooke's experience includes company formation and acquisitions, as well as public listings on the NYSE, NASDAQ and ASX exchanges. Mr Brooke is licensed in clinical medicine by the Medical Board of Victoria, Australia and his postgraduate work was in anaesthetics and intensive care.

Companies and Roles

Company
Title
Tenure
Since
CYP
Cynata Therapeutics Limited
  • Non-Executive Director
  • Non-Executive Chairman
5yrs, 2mthMay 2019
ACW
Actinogen Medical Limited
  • Non-Executive Chairman
  • Non-Executive Director
3yrs, 5mthFeb 2021
ACR
Acrux Limited
  • Non-Executive Director
8yrs, 1mthJun 2016

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ACW
Actinogen Medical Limited
05/06/2416,054,0392,801,3656,101,592N/A
CYP
Cynata Therapeutics Limited
16/05/24N/A257,3432,569,767N/A
ACR
Acrux Limited
20/12/231,296,080394,221N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ACW
Actinogen Medical Limited
05/06/24
Issued
1,003,378$0.025$25,084Rights issue
ACW
Actinogen Medical Limited
05/06/24
Issued
175,085$0.025$4,377Rights issue
ACW
Actinogen Medical Limited
05/06/24
Issued
589,232$0.029$17,087Rights issue
CYP
Cynata Therapeutics Limited
16/05/24
Expiry
300,000$0.280$84,000Options expired
ACR
Acrux Limited
20/12/23
Buy
138,187$0.045$6,218Conversion of securities